1-Cyanmethyl-4-(3-methoxy-phenyl)-piperazin | 93475-48-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-Cyanmethyl-4-(3-methoxy-phenyl)-piperazin
• 英文别名: [4-(3-methoxy-phenyl)-piperazin-1-yl]-acetonitrile；[4-(3-Methoxy-phenyl)-piperazin-1-yl]acetonitrile；2-[4-(3-methoxyphenyl)piperazin-1-yl]acetonitrile
• CAS: 93475-48-0
• 化学式: C₁₃H₁₇N₃O
• mdl: MFCD11131828
• 分子量: 231.297
• InChiKey: JFKZOQDQQRLEES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  39.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  氯乙腈 、 1-(3-甲氧基苯基)哌嗪 在 potassium carbonate 作用下， 反应 18.0h， 生成 1-Cyanmethyl-4-(3-methoxy-phenyl)-piperazin
  参考文献：
  名称：

  4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamides: Selective dopamine D3 receptor partial agonists

  摘要：

  A series of 4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamide dopamine (DA) D-3 receptor agonists has been identified. These compounds were found to be selective for DA D-3 over D-2 receptors and were shown to be partial to full agonists as measured by stimulation of mitogenesis in D-3-transfected CHO p-5 cells. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00231-4

文献信息

• 3-imidazolyl-indoles for the treatment of proliferative diseases
  申请人：Novartis AG

  公开号：US08053457B2

  公开（公告）日：2011-11-08

  The invention relates to 3-heterocyclyl indolyl compounds of formula I capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively: wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

  本发明涉及式I的3-杂环基吲哚化合物，能够抑制p53或其变异体与MDM2和/或MDM4或其变异体之间的相互作用：其中R1，R2，R3，R4，RA，Y和Y如说明书所定义。由于其活性，这些化合物在治疗由MDM2和/或MDM4或其变异体活性介导的各种疾病和疾病，如炎症或增殖性疾病或细胞保护方面是有用的。
• 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases
  申请人：Boettcher Andreas

  公开号：US20100125064A1

  公开（公告）日：2010-05-20

  The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula I, wherein R 1 , R 2 , R 3 , R 4 , R A , Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

  本发明涉及能够抑制p53或其变体与MDM2和/或MDM4或其变体相互作用的3-杂环基吲哚化合物，其中所述化合物具有式I，其中R1、R2、R3、R4、RA、Y和Y的定义见说明书。由于其活性，这些化合物可用于治疗由MDM2和/或MDM4或其变体介导的各种疾病和疾病，例如炎症性或增殖性疾病或细胞保护。
• US8053457B2
  申请人：——

  公开号：US8053457B2

  公开（公告）日：2011-11-08
• 4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamides: Selective dopamine D3 receptor partial agonists
  作者：Shelly A. Glase、Hyacinth C. Akunne、Thomas G. Heffner、Stephen J. Johnson、Suzanne R. Kesten、Robert G. MacKenzie、Peter J. Manley、Thomas A. Pugsley、Jon L. Wright、Lawrence D. Wise

  DOI：10.1016/0960-894x(96)00231-4

  日期：1996.6

  A series of 4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamide dopamine (DA) D-3 receptor agonists has been identified. These compounds were found to be selective for DA D-3 over D-2 receptors and were shown to be partial to full agonists as measured by stimulation of mitogenesis in D-3-transfected CHO p-5 cells. Copyright (C) 1996 Elsevier Science Ltd